AMD_CNV_HIF

Investigating the role of HIFs in myeloid cells during experimental choroidal neovascularisation

Coordinatore	UNIVERSITY COLLEGE LONDON    more  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Malgorzata Cognome: Kielbasa Email: send email Telefono: +44 2 031083064
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	231˙283 €
EC contributo	231˙283 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IEF
Funding Scheme	MC-IEF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-05-01   -   2016-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Malgorzata Cognome: Kielbasa Email: send email Telefono: +44 2 031083064	UK (LONDON)	coordinator	231˙283.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Age-related macular degeneration (AMD) is the commonest cause of blindness in the developed world. AMD is a progressive disorder of the outer retina characterised by the accumulation of extracellular deposits and chronic inflammation at the level of Bruch’s basement membrane. Photoreceptor cell death is the result of progressive (‘geographic’) atrophy of supporting retinal pigment epithelium (RPE), or disruption by pathological neovascularisation that arises from the choroid and penetrates defects in Bruch’s membrane. Choroidal neovascularisation (CNV) develops in response to the up-regulation of multiple pro-angiogenic cytokines, including vascular endothelial growth factor (VEGF), in the context of an abnormal extracellular matrix. The outcome of neovascular AMD can be improved by intraocular delivery of VEGF inhibitors but this is incompletely effective, indicating the involvement of additional parallel pathways or compensatory mechanisms. There is a clear unmet need for more effective treatments. In this fellowship I will investigate the hypothesis that HIF activation in myeloid cells is responsible for neovascular AMD. By defining the role of HIF in myeloid cells in the development of experimental CNV I aim to identify new opportunities to improve the efficacy of therapeutic intervention.'